Highlights argenx SE

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 16:55:00 15/05/2026 BST			After hours 20:59:58
693.20 ^EUR	-0.14%		687.30	-0.85%

05-12	Argenx SE Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 10:40 AM
05-12	ARGENX : Bernstein reiterates its Buy rating	ZD

Highlights

05-11	US FDA Approves Expansion of Indication for Argenx's Vyvgart	MT
05-08	Argenx announces U.S. FDA approval expanding Vyvgart and Vyvgart Hytrulo for use in all adult patients living with gMG	RE
05-08	Argenx SE Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG	CI
05-07	Argenx Q1 Profit, Total Operating Income Increase	MT
05-07	Argenx SE Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Argenx Q1 total operating income USD 1.313 bln	RE
05-07	Argenx Logs Improved Q1 Profit, Product Net Sales	MT
04-18	Argenx SE Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP	CI
04-18	Argenx brings neuromuscular leadership to AAN 2026 with new data supporting broader Vyvgart use across MG and CIDP	RE
03-06	Argenx SE Presents New Data and Pipeline Updates At 2026 AAN Annual Meeting	CI
02-26	Argenx's Vyvgart Improves Ocular Myasthenia Gravis Symptoms in Late-stage Trial	MT
02-26	Argenx reports $1.3 billion in Q4 global product net sales	RE
02-26	Argenx Q4 Earnings Decline, Operating Income Rises	MT
02-26	Argenx SE Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-26	Argenx Se Announces Positive Topline Results from Phase 3 Adapt Oculus Trial of Vyvgart in Ocular Myasthenia Gravis	CI
02-26	Argenx Reports Higher FY25 Attributable Profit, Operating Income	MT
01-13	Argenx Says it Gets US FDA's Acceptance for Priority Review for Vyvgart sBLA	MT
01-13	Argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG	CI
01-13	Argenx: FDA accepts priority review sBLA for Vyvgart in seronegative gMG	RE
01-12	Argenx preliminary FY global product net sales $4.15 bln	RE
01-05	Karen Massey to become CEO of argenx	RE
12-15	Argenx SE Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease	CI
12-15	Argenx: UplighTED studies of efgartigimod SC in Thyroid Eye Disease to be discontinued	RE
11-18	Argenx announces results of extraordinary general meeting of shareholders	RE
11-05	Argenx SE Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada	CI